![]()
|
Report Date : |
31.10.2007 |
IDENTIFICATION
DETAILS
|
Name : |
ISLAMIC
PHARMACEUTICALS CHEMICALS & MEDICAL SUPPLIES CO SAE |
|
|
|
|
Registered Office : |
496 El Horreya Road,
Boulkley, Ramleh, P O Box 12, Sidi Gaber, Alexandria |
|
|
|
|
Country : |
Egypt |
|
|
|
|
Financials (as on) : |
31.12.2006 |
|
|
|
|
Date of Incorporation : |
1982 |
|
|
|
|
Com. Reg. No.: |
221697, Alexandria |
|
|
|
|
Legal Form : |
Egyptian Joint Stock Company |
|
|
|
|
Line of Business : |
Manufacture and
marketing of over 150 medical products. |
RATING &
COMMENTS
|
MIRA’s Rating : |
Aa |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
Maximum Credit Limit : |
US$ 2,500,000 |
|
|
|
|
Status : |
Excellent |
|
|
|
|
Payment Behaviour : |
Regular |
|
|
|
|
Litigation : |
Clear |
Company Name : ISLAMIC PHARMACEUTICALS CHEMICALS & MEDICAL SUPPLIES
CO SAE
Also Known As : PHARCO PHARMACEUTICALS
Country of Origin : Egypt
Legal Form : Egyptian Joint Stock Company
Registration Date : 1982
Commercial Registration Number : 221697, Alexandria
Authorised Capital : £E 200,000,000
Issued Capital : £E 50,000,000
Paid up Capital : £E 50,000,000
Total Workforce : 1,000
Line of Business : Production of medical products.
Financial Condition : Good
Payments : Prompt
Operating Trend : Steady
ISLAMIC
PHARMACEUTICALS CHEMICALS & MEDICAL SUPPLIES CO SAE
PHARCO
PHARMACEUTICALS
Street : 496 El Horreya Road
Area : Boulkley, Ramleh
PO Box : 12, Sidi Gaber
Town : Alexandria
Country : Egypt
Telephone : (20-3) 5823745 / 5821999 / 5839670
Facsimile : (20-3) 5830958
Email : pharco@pharco.com.eg
Subject operates
from a large suite of offices that are owned and located in the Central
Business Area of Alexandria.
Location Description
·
Alexandria-Cairo
Desert Road, Km-31, Plot 8-15 Owned
factory premises
Amreya
Alexandria
Tel : (20-3) 4480440 / 4480720
/ 44800130 / 4480140
Fax : (20-3) 4480730 / 4486560
·
2 El
Gomhoureya Square Rented
office premises
Hadayek El Qobba
Cairo
Tel : (20-2) 3920845 / 3920529
·
Dr Hassan
Abbas Helmi Managing
Director
·
Dr Sherine
Hassan Abbas Helmi Director
·
Yasha Abbas
Helmi Director
·
Abdel Moneim
El Toukhi Director
·
El Prince
Mahmoud Tawfik Finance
Manager
·
Abdel Hamza Engineering
Manager
·
Mohamed
Youssef Projects
Manager
·
Mamdouh Abbas Ibrahim Factory
Manager
·
Dr Mohamed
Ibrahim Hamza Planning
Manager
·
Fayez El Sobky Administration
Manager
·
Nagi El Saif Operations
Manager
·
Mohamed Rakha Export
Manager
·
Ahmed El Sayed
Ahmed El Shahawi Maintenance
Manager
·
Diaa El Din
Ibrahim Branch
Manager – Cairo
Date of Establishment : 1982
Legal Form :
Societe Anonyme Egyptienne
- SAE (Egyptian Joint Stock Company)
Commercial Reg. No. : 221697,
Alexandria
Authorised
Capital : £E 200,000,000
Issued Capital : £E
50,000,000
Paid up Capital : £E 50,000,000
·
Dr Hassan
Abbas Helmi
·
Dr Sherine
Hassan Abbas Helmi
·
Yasha Abbas
Helmi
·
Faisal Islamic
Bank of Egypt
1113 Cornich El Nil Street
Cairo
Tel : (20-2) 753165 / 753109
Note to the Legal Form
The Egyptian Company Law provides that the capital of a Societe Anonyme Egyptienne - SAE – should not be less than £E 500,000 if shares are offered to the public and £E 250,000 if not. If shares are offered to the public they are freely transferable, if not, transfer may be restricted. Liability of shareholders is limited.
Operations : Engaged in the manufacture and marketing of
over 150 medical products, including carbohydrates, proteins and enzymes,
barbiturates, sulphonamides, glycacoides, antibiotics, penicillin, as well as pharmaceutical preparations for
the cardio-vascular system and chemotherapeutic agents.
Subject’s agents
include:
·
International
Trading Pharmaceuticals Laboratories Inc. United
States of America
·
Tunsal
International Company Limited Nigeria
·
Pharmaplus
Pharmaceuticals & Beauty Care LTD Kenya
·
Ramada Trading
Co Ethiopia
·
El Nasr Export
Import Co Zimbabwe
·
Pharco
Pharmaceuticals Uganda LTD Uganda
·
Medix
International Malawi
·
Soprophal
Spa Algeria
·
U.M.A Line
Group Tunisia
·
Qatar
Pharmacy Qatar
·
Modern Drug
Store Jordan
·
Kambal International
Agencies Sudan
·
Abdulrehman
Algosaibi General Trading Bureau Saudi
Arabia
·
Gulf Drug LLC United
Arab Emirates
·
Boushahri
Group WLL Kuwait
·
Jaffar
Pharmacy Bahrain
·
Muttrah
Pharmacy LLC Oman
·
Al Fath
Trading Co Yemen
Import Countries
: Germany, France, Italy,
the Netherlands, Austria and the United States of America.
Principal
Suppliers:
·
Mead Johnson United States of America
·
Duphar Netherlands
·
Biochemee Austria
·
Merz Germany
·
Latema France
Export Countries
: Subject exports to over
30 countries covering Africa, the Middle East, Europe and the United States of
America.
Operating Trend
: Steady
Subject has a
workforce of approximately 1,000 employees.
Financial highlights
provided by outside sources are given below :
Currency : Egyptian
Pound (£E)
Year
Ending 31/12/05: Year
Ending 31/12/06:
Total Revenue £E 305,470,000 £E 338,000,000
Local sources
consider subject’s financial condition to be Good.
·
Faisal Islamic
Bank of Egypt
7 Victor Pasilly Street
El Azareta
Alexandria
Tel : (20-3) 4911653
·
Commercial
International Bank (CIB)
61 Sultan Hussein Street
Alexandria
Tel : (20-3) 4824643 / 4834255
Fax : (20-3) 4832240
·
National Societe
Generale Banque SAE
Evergreen Building
10 Talaat Harb Street
PO Box : 2664
Cairo
Tel : (20-2) 5749376
Fax : (20-2) 5776249
·
Banque du
Caire SAE
Sesostris
Branch
1 Hagar
El Newateyah Street
Alexandria
Tel:
(20-3) 5744532
·
Citibank
95, 26th July Street
Azarita
Alexandria
Tel: (20-3) 4834363 / 4840342
Fax: (20-3) 4884363
Subject’s payment
record is reported to be met in a generally prompt manner.
Date of transaction October 2005 April 2006 December 2006
Credit amount 612,000 1,000,000 100,000
Amount overdue 0 0 0
Payment terms 60
days 90 days 60 days
Payment Method Letters
of Credit Letters of Credit Letters of Credit
Paying record No
Complaints No Complaints No Complaints
Currency Pounds
Sterling US Dollars US Dollars
Opinion on the credit figure of US$ 100,000
Pharco Pharmaceuticals is one of the largest Egyptian companies in the field of pharmaceutical products, and was ranked as the second best selling Egyptian pharmaceutical company in 2000, with exports being sent to over 30 countries.
The company was established in 1982 and has a good reputation for the quality of its products. The operating history is clear with payment obligations met in a generally prompt manner. Local sources report that the subject would not enter into financial transactions it could not see its way clear to fulfil and as such the above credit figure is deemed admissible.
RATING
EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General unfavourable
factors will not cause fatal effect. Satisfactory capability for payment of
interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Unfavourable & favourable factors carry similar weight in credit
consideration. Capability to overcome financial difficulties seems
comparatively below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
NR |
In view of the lack of information, we have no basis upon which to
recommend credit dealings |
No Rating |
|
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a composite
of weighted scores obtained from each of the major sections of this report. The
assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)